Combined Permanent Implant and External-Beam Radiation Therapy for Prostate Cancer

Seminars in Radiation Oncology

Volumn 18, Issue 1, 2008, Pages 23-34

  Soto, Daniel E ^a   McLaughlin, Patrick W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMPLANT; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM FISTULA; URETHRA FISTULA;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36849061627     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.09.004     Document Type: Article

References (99)

1. Stamey T.A., Caldwell M., McNeal J.E., et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?. J Urol 172 (2004) 1297-1301
2. Hankey B.F., Feuer E.J., Clegg L.X., et al. Cancer surveillance series: interpreting trends in prostate cancer-part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91 (1999) 1017-1024
3. Derweesh I.H., Kupelian P.A., Zippe C., et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 22 (2004) 300-306
4. Frank S.J., Grimm P.D., Sylvester J.E., et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy 6 (2007) 2-8
5. Critz F.A., and Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172 (2004) 2232-2238
6. Blasko J.C., Grimm P.D., Sylsvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57 (2000) 273-278
7. Merrick G.S., Wallner K.E., Butler W.M., et al. Permanent prostate brachytherapy: is supplemental external-beam radiation therapy necessary?. Oncology (Williston Park) 20 (2006) 514-522 discussion 522-525
8. Potters L., Fearn P., and Kattan M.W. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy 1 (2002) 36-41
9. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
10. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
11. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1233-1239
12. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
13. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
14. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1493
15. Critz F.A., Williams W.H., Levinson A.K., et al. Simultaneous irradiation for prostate cancer: intermediate results with modern techniques. J Urol 164 (2000) 738-741 discussion 741-743
16. Pickett B., Kurhanewicz J., Coakley F., et al. Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 1047-1055
17. Critz F.A., Williams W.H., Benton J.B., et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163 (2000) 1085-1089
18. Toledano A., Chauveinc L., Flam T., et al. PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure: a study of 295 patients with a minimum 3-year followup. Brachytherapy 5 (2006) 122-126
19. Zagar T.M., Stock R.G., Cesaretti J.A., et al. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Brachytherapy 6 (2007) 26-33
20. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 56 (2000) 899-905
21. Tran A., Wallner K., Merrick G., et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 63 (2005) 150-154
22. Zeitlin S.I., Sherman J., Raboy A., et al. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 160 (1998) 91-95 discussion 95-96
23. Theodorescu D., Gillenwater J.Y., and Koutrouvelis P.G. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 89 (2000) 2085-2091
24. Iversen P., Bak M., Juul N., et al. Ultrasonically guided 125iodine seed implantation with external radiation in management of localized prostatic carcinoma. Urology 34 (1989) 181-186
25. Ragde H., Elgamal A.A., Snow P.B., et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83 (1998) 989-1001
26. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
27. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
28. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
29. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 46 (2000) 221-230
30. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer 97 (2003) 979-983
31. Wallner K., Merrick G., True L., et al. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 75 (2005) 307-310
32. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
33. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
34. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645-653
35. Papagikos M., Rossi P., and deGuzman A. A simple robust model using D90, percent positive biopsies, and clinical risk group predicts freedom from biochemical recurrence following low-dose-rate prostate brachytherapy. Int J Radiat Oncol Biol Phys 66 (2006) S381 (abstr)
36. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280 (1998) 969-974
37. Choi S., Wallner K.E., Merrick G.S., et al. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J 10 (2004) 175-180
38. Orio P., Wallner K., Merrick G., et al. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys 67 (2007) 342-346
39. Allen Z., Merrick G., Wallner K., et al. Extracapsular radiation dose annulus correlates with biochemical control in low-risk prostate brachytherapy patients: results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) S359 (abstr)
40. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 85 (1999) 2630-2637
41. Chao K.K., Goldstein N.S., Yan D., et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 65 (2006) 999-1007
42. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 55 (2000) 382-386
43. Teh B.S., Bastasch M.D., Mai W.-Y., et al. Predictors of extracapsular extension and its radial distance in prostate cancer: implications for prostate IMRT, brachytherapy, and surgery. Cancer J 9 (2003) 454-460
44. Reed D.R., Wallner K.E., Merrick G., et al. Isodose patterns in patients with inadequate prostate brachytherapy coverage. Int J Radiat Oncol Biol Phys 56 (2003) 1480-1487
45. Kestin L., Goldstein N., Vicini F., et al. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. Int J Radiat Oncol Biol Phys 54 (2002) 686-697
46. Stock R.G., Lo Y.C., Gaildon M., et al. Does prostate brachytherapy treat the seminal vesicles?. A dose-volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 45 (1999) 385-389
47. Nedea E., Wallner K., Reed D., et al. Extraprostatic seed placement and its effect on seed loss. Cancer J 11 (2005) 147-151
48. Roach III M., Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
49. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
50. Seaward S.A., Weinberg V., Lewis P., et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 1055-1062
51. Rasp G., Pisansky T., Haddock M., et al. Elective pelvic nodal irradiation in patients with clinically localized prostate cancer at high risk for pelvic nodal involvement. Int J Radiat Oncol Biol Phys 36 (1996) 245 (abstr)
52. Pan C.C., Kim K.Y., Taylor J.M., et al. Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 53 (2002) 1139-1145
53. Horwitz E.M., Hanlon A.L., Pinover W.H., et al. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 41 (1998) 519-523
54. Jacob R., Hanlon A.L., Horwitz E.M., et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61 (2005) 695-701
55. Vargas C.E., Galalae R., Demanes J., et al. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation. Int J Radiat Oncol Biol Phys 63 (2005) 1474-1482
56. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
57. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
58. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 669-677
59. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of radiation dose to the urethra on brachytherapy-related dysuria. Brachytherapy 4 (2005) 45-50
60. Merrick G.S., Butler W.M., Wallner K.E., et al. Risk factors for the development of prostate brachytherapy related urethral strictures. J Urol 175 (2006) 1376-1380 discussion 1381
61. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
62. Merrick G.S., Butler W.M., Galbreath R.W., et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52 (2002) 893-902
63. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 437-447
64. Lee W.R., Bae K., Lawton C.A., et al. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy 5 (2006) 239-243
65. Merrick G.S., Butler W.M., Wallner K.E., et al. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis. Brachytherapy 4 (2005) 241-251
66. Acher P., Popert R., Nichol J., et al. Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. Int J Radiat Oncol Biol Phys 65 (2006) 694-698
67. Potters L., Calugaru E., Jassal A., et al. Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy?. Int J Radiat Oncol Biol Phys 65 (2006) 1014-1019
68. McLaughlin P.W., Narayana V., Drake D.G., et al. Comparison of MRI pulse sequences in defining prostate volume after permanent implantation. Int J Radiat Oncol Biol Phys 54 (2002) 703-711
69. McLaughlin P.W., Troyer S., Berri S., et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys 63 (2005) 479-491
70. Merrick G.S., Butler W.M., Lief J.H., et al. Biochemical outcome for hormone-naive patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J 8 (2002) 322-327
71. D'Amico A.V., Renshaw A.A., Schultz D., et al. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy. Int J Radiat Oncol Biol Phys 45 (1999) 847-851
72. Groll R., Fleshner N.E., Sugar L., et al. Clinical significance of biopsy-derived primary Gleason score among radical prostatectomy candidates with Gleason 7 tumors. Urology 59 (2002) 551-554
73. Beard C.J., Chen M.H., Cote K., et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys 58 (2004) 19-24
74. Bonin S.R., Hanlon A.L., Lee W.R., et al. Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. Cancer 79 (1997) 75-80
75. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer. Cancer J 11 (2005) 234-240
76. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy. Urology 66 (2005) 1048-1053
77. Merrick G.S., Butler W.M., Galbreath R.W., et al. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys 52 (2002) 664-673
78. Merrick G.S., Butler W.M., Galbreath R.W., et al. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J 8 (2002) 79-80
79. Merrick G.S., Butler W.M., Wallner K.E., et al. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. Urology 64 (2004) 754-759
80. Merrick G.S., Butler W.M., Wallner K.E., et al. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external-beam radiation. Cancer J 10 (2004) 54-60
81. Stock R.G., Ho A., Cesaretti J.A., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
82. Kupelian P., Kuban D., Thames H., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 61 (2005) 415-419
83. Merrick G.S., Butler W.M., Wallner K.E., et al. Dysuria after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 979-985
84. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
85. Merrick G.S., Butler W.M., Wallner K.E., et al. Rectal function following brachytherapy with or without supplemental external beam radiation: results of two prospective randomized trials. Brachytherapy 2 (2003) 147-157
86. Merrick G.S., Butler W.M., Wallner K.E., et al. Late rectal function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 57 (2003) 42-48
87. Sherertz T., Wallner K., Merrick G., et al. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. Brachytherapy 3 (2004) 130-135
88. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
89. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
90. McLaughlin P.W. Dosimetry seminar. ASTRO. November 5-9, 2006, Philadelphia, PA (2006)
91. Han B., Wallner K., Aggarwal S., et al. Treatment margins for prostate brachytherapy. Semin Urol Oncol 18 (2000) 137-141
92. Reed D.R., Wallner K., Ford E., et al. Effect of post-implant edema on prostate brachytherapy treatment margins. Int J Radiat Oncol Biol Phys 63 (2005) 1469-1473
93. Patel A.B., Waterman F.M., and Dicker A.P. A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy. Brachytherapy 2 (2003) 223-228
94. Waterman F.M., and Dicker A.P. Probability of late rectal morbidity in 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 342-353
95. McLaughlin P., Narayana V., Pan C., et al. Comparison of day 0 and day 14 dosimetry for permanent prostate implants using stranded seeds. Int J Radiat Oncol Biol Phys 64 (2006) 144-150
96. McLaughlin P.W. Prostate Cancer Treatment Symposium. ASTRO. November 5-9, 2006, Philadelphia, PA (2006)
97. McLaughlin P.W., Narayana V., Berri S., et al. Decreased Intra-fraction prostate motion permanent implant relative to non-implant patients. Brachytherapy 5 (2006) 80 (abstr)
98. Narayana V., Spirou G., Berri S., et al. Permanent prostate implants: dose to critical structures inferior to the prostate apex. Med Phys 33 (2006) 2128 (abstr)
99. Narayana V., Heckman P., and McLaughlin P.W. IMRT for the prostate following brachytherapy. IOMP; World Congress on Medical Physics and Biomedical Engineering, August 27-September 1 (2006)